Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 26;42(12):113507.
doi: 10.1016/j.celrep.2023.113507. Epub 2023 Dec 1.

VEGF-C-expressing TAMs rewire the metastatic fate of breast cancer cells

Affiliations
Free article

VEGF-C-expressing TAMs rewire the metastatic fate of breast cancer cells

Kaveri Banerjee et al. Cell Rep. .
Free article

Abstract

The expression of pro-lymphangiogenic VEGF-C in primary tumors is associated with sentinel lymph node metastasis in most solid cancer types. However, the impact of VEGF-C on distant organ metastasis remains unclear. Perivascular tumor-associated macrophages (TAMs) play a crucial role in guiding hematogenous spread of cancer cells by establishing metastatic pathways within the tumor microenvironment. This process supports breast cancer cell intravasation and metastatic dissemination. We show here that VEGF-C-expressing TAMs reduce the dissemination of mammary cancer cells to the lungs while concurrently increasing lymph node metastasis. These TAMs express podoplanin and interact with normalized tumor blood vessels expressing VEGFR3. Moreover, clinical data suggest inverse association between VEGF-C-expressing TAMs and breast cancer malignancy. Thus, our study elucidates the paradoxical role of VEGF-C-expressing TAMs in redirecting cancer cells to preferentially disseminate to lymph nodes rather than to lungs, partially achieved by normalizing tumor blood vessels and promoting lymphangiogenesis.

Keywords: CP: Cancer; VEGFR3; breast cancer; hematogenous cancer cell spreading; hypoxia; lymph node metastases; podoplanin; tumor microenvironment of metastasis; tumor-associated macrophages; vascular endothelial growth factor-C; vascular normalization.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests J.H. has obtained speaker’s honoraria or advisory board remunerations from Roche, Novartis, Pfizer, EliLilly, MSD, Seagen, and AstraZeneca and has received institutional research support from Cepheid, Roche, AstraZeneca, and Novartis. J.H. is a co-founder and shareholder of Stratipath AB. A.Ö. is co-founder of TECKNET AB and has in recent years received research support from IPSEN AB. J.B. has research grants from Amgen, AstraZeneca, Bayer, Merck, Pfizer, Roche, and Sanofi-Aventis to Karolinska Institutet and/or University Hospital. No personal payments. Co-author on a chapter on "Prognostic and Predictive factors in early, non-metastatic breast cancer" in UpToDate. Honoraria to Asklepios Medicin HB. Stocks in Stratipath AB, a company involved in AI-based diagnostics for breast cancer. Chairperson for Coronis and Asklepios Cancer Research HB. Honoraria from Roche and AstraZeneca for chairmanship and lectures at scientific meetings and consultations for Stratipath AB.

Publication types

Substances

LinkOut - more resources